Pivotal readout

DBV presents further VITESSE phase 3 results for VIASKIN peanut patch in young children

In the 654-child VITESSE trial in ages 4 to 7, 46.6% on the VIASKIN patch met the month-12 responder bar compared with 14.8% on placebo. New analyses showed milder reactions at food challenge and immune changes in line with allergen immunotherapy. Average adherence was 96.1%; the patch is still investigational.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call